Xintela AB Cash Flow Conversion Efficiency

Latest as of September 2025: 0.242x

Xintela AB cash flow conversion efficiency. Based on the latest financial reports, Xintela AB (XINT) has a cash flow conversion efficiency ratio of 0.242x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.74 Million ≈ $-724.90K USD) by net assets (Skr-27.88 Million ≈ $-3.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Xintela AB (2013–2024)

Cash flow conversion efficiency of Xintela AB from 2013 to 2024. This chart illustrates how Xintela AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XINT stock price for real-time trading data and today's change.

Xintela AB Cash Flow Conversion Ratio Explained

Xintela AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Xintela AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xintela AB ranked by their cash flow conversion efficiency. Also see market value of Xintela AB for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Tvardi Therapeutics, Inc. NASDAQ:TVRD	-1.101x
i2S SA PA:ALI2S	0.169x
TAG Oil Ltd. V:TAO	-0.021x
BSL Corp Bhd KLSE:7221	-0.260x
Adventa Bhd KLSE:7191	-0.008x
Volt Power Group Ltd AU:VPR	0.043x
G Capital Bhd KLSE:7676	0.031x
Proteomics International Laboratories Ltd AU:PIQ	-0.132x

Annual Cash Flow Conversion Efficiency for Xintela AB (2013–2024)

The table below shows the annual cash flow conversion efficiency of Xintela AB from 2013 to 2024. Review XINT free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr-5.95 Million ≈ $-640.32K	Skr-40.70 Million ≈ $-4.38 Million	6.841x	+156.41%
2023-12-31	Skr4.38 Million ≈ $471.36K	Skr-53.12 Million ≈ $-5.72 Million	-12.127x	-77.41%
2022-12-31	Skr5.78 Million ≈ $621.70K	Skr-39.49 Million ≈ $-4.25 Million	-6.836x	+37.10%
2021-12-31	Skr3.95 Million ≈ $424.76K	Skr-42.89 Million ≈ $-4.62 Million	-10.867x	-1306.49%
2020-12-31	Skr27.61 Million ≈ $2.97 Million	Skr-21.33 Million ≈ $-2.30 Million	-0.773x	+76.68%
2019-12-31	Skr9.32 Million ≈ $1.00 Million	Skr-30.89 Million ≈ $-3.32 Million	-3.313x	-377.25%
2018-12-31	Skr44.95 Million ≈ $4.84 Million	Skr-31.20 Million ≈ $-3.36 Million	-0.694x	+11.03%
2017-12-31	Skr18.41 Million ≈ $1.98 Million	Skr-14.37 Million ≈ $-1.55 Million	-0.780x	+5.90%
2016-12-31	Skr20.98 Million ≈ $2.26 Million	Skr-17.40 Million ≈ $-1.87 Million	-0.829x	+35.11%
2015-12-31	Skr7.46 Million ≈ $802.92K	Skr-9.54 Million ≈ $-1.03 Million	-1.278x	-193.91%
2014-12-31	Skr9.54 Million ≈ $1.03 Million	Skr-4.15 Million ≈ $-446.50K	-0.435x	+26.64%
2013-12-31	Skr5.08 Million ≈ $546.88K	Skr-3.01 Million ≈ $-324.14K	-0.593x	--

About Xintela AB

ST:XINT Sweden Biotechnology

Market Cap

$11.13 Million

Skr103.39 Million SEK

Market Cap Rank

#26642 Global

#561 in Sweden

Share Price

Skr0.15

Change (1 day)

-5.16%

52-Week Range

Skr0.15 - Skr0.39

All Time High

Skr8.60